INTERIM REPORT

JANUARY 1 - JUNE 30, 2026

Positive development across AddLife's companies

AddLife's companies are performing well across the board, with stronger margins, good growth and increased cash flow. Our improvement efforts are yielding clear results, and our recently acquired companies are making a significant contribution to earnings growth. At the same time, we are actively pursuing further acquisitions.
Fredrik Dalborg, President and CEO

SECOND QUARTER

- Net sales increased by 6 percent to SEK 2,721 million (2,578). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent and acquired growth amounted to 3 percent.
- EBITA increased by 11 percent to SEK 342 million (307), corresponding to an EBITA margin of 12.6 percent (11.9).
- Profit after tax increased by 30 percent to SEK 130 million (100).
- Earnings per share amounted to SEK 1.06 (0.83).
- Cash flow from operating activities amounted to SEK 165 million (119).
- During the quarter, the acquisition of CoaChrom Diagnostica GmbH, Austria, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 110 million.

JANUARY – JUNE, 2026

- Net sales increased by 2 percent to SEK 5,366 million (5,280). Adjusted for operations divested in December 2025, organic growth amounted to 3 percent, acquired growth amounted to 2 percent, and exchange rate effects had a negative impact of 2 percent.
- EBITA increased by 4 percent to SEK 674 million (650), corresponding to an EBITA margin of 12.6 percent (12.3). Exchange rate effects had a negative impact of 2 percent on EBITA.
- Profit after tax increased by 17 percent to SEK 258 million (220).
- Earnings per share amounted to SEK 2.11 (1.81). For the latest 12-month period, earnings per share amounted to 4.89 (2.76).
- Cash flow from operating activities amounted to SEK 269 million (359).
- The equity ratio was 43 percent (43).
- Return on working capital (P/WC) amounted to 61 percent (62).
- During the interim period, two acquisitions were completed. The acquisitions are expected to contribute annual net sales of approximately SEK 185 million.

SEKm	Q2 2026	Q2 2025	Δ %	Jan-Jun 2026	Jan-Jun 2025	Δ %	Jul 2025-Jun 2026	Full year 2025
Net sales	2,721	2,578	6	5,366	5,280	2	10,528	10,442
EBITA	342	307	11	674	650	4	1,441	1,417
EBITA margin, %	12.6	11.9		12.6	12.3		13.7	13.6
Adjusted EBITA	342	307	11	674	650	4	1,283	1,259
Adjusted EBITA margin, %	12.6	11.9		12.6	12.3		12.2	12.1
Profit/loss before taxes	189	146	29	372	318	17	826	772
Profit for the period	130	100	30	258	220	17	600	562
Earnings per share (EPS), before/after dilution, SEK	1.06	0.83	28	2.11	1.81	17	4.89	4.59
Cash flow from operating activities	165	119	38	269	359	-25	1,302	1,392

4%
ORGANIC GROWTH

11%
EBITA GROWTH

12.6%
EBITA MARGIN

61%
P/WC

Positive development across AddLife's companies

> *"AddLife's companies are performing well across the board, with stronger margins, good growth and increased cash flow. Our improvement efforts are yielding clear results, and our recently acquired companies are making a significant contribution to earnings growth. At the same time, we are actively pursuing further acquisitions."*
>
> **Fredrik Dalborg, President and CEO**

Margins strengthen

Continuous efficiency improvements and optimisation of operations are a central part of our business model. Our long-term initiative to develop the portfolio towards more advanced products continue to strengthen gross margins. Overall, these initiatives contributed to improved margins in both Labtech and Medtech during the quarter. Advanced products create greater value for our customers through improved clinical outcomes and more efficient processes. At the same time, they require specialised expertise with high availability and close collaboration with customers. This is something that AddLife's companies have built up during a long period of time.

Improvement initiatives show clear results

Structured improvement initiatives are under way in several of our companies, and these efforts are yielding clear results.

Within Homecare, we have recently implemented a number of improvement measures in several companies. New products have been launched and sales are trending positively. Taken together, this has resulted in improved margins, and during the quarter Homecare made a positive contribution to AddLife's average margin.

We have also carried out extensive improvement initiatives within ophthalmic surgery, resulting in lower costs, an updated product portfolio and a clearer sales focus. Margins have improved gradually, and this positive trend continued during the second quarter, demonstrating stability and favourable prospects.

Sales in a positive trend

Group sales increased by 6 percent during the quarter. The underlying organic growth amounted to 4 percent, while acquisitions contributed a further 3 percentage points.

In Medtech, organic growth was 5 percent, adjusted for the previously divested endoscopy business in the United Kingdom. Sales developed strongly during the quarter, despite doctors' strikes in Spain and continued subdued capital equipment sales in healthcare in the United Kingdom, which held back demand somewhat.

Sales in the Nordic region developed well, driven primarily by strong sales of advanced hospital products. Growth was also good within Homecare.

In Labtech, organic sales growth was 3 percent, while acquisitions contributed 4 percent. Positive effects from previously won tenders continued during the quarter and contributed to good sales of both instruments and consumables. Demand in the research segment has improved for some time and strengthened further during the quarter. Sales were strong in several Eastern European countries, driven by economic growth and increased investment in healthcare, diagnostics and research.

Acquisitions contribute to earnings growth

Our four recently acquired companies are performing well and made a clear contribution to earnings growth during the quarter. We continue to have a large number of active acquisition processes and are working in parallel to build a long-term pipeline of potential acquisition candidates. AddLife has built strong acquisition capabilities over a long period of time, with clear priorities and criteria, established roles and responsibilities, and strengthened resources. We also systematically and continuously develop our processes based on experience and future ambitions.

Summary and outlook

During the second quarter, we saw positive development in most parts of the business. Sales, earnings and operating cash flow developed well, driven by the dedicated and structured work carried out within our companies. Particularly encouraging are the clear improvements within Homecare and ophthalmic surgery, where extensive improvement efforts have been under way for a longer period.

Our initiatives in advanced products also continue to contribute positively to margin improvement, and we expect to see continued good results from these initiatives. Acquisition activity remains high, creating attractive opportunities to further develop the Group through complementary acquisitions.

AddLife enters the second half of the year with stable underlying growth, strong margins, a well-positioned business and initiatives that create the conditions for continued positive development.

I would like to congratulate our companies on their good results during the quarter and thank all employees for their strong commitment. At the same time, I would like to express my appreciation to our customers and partners for their trust and long-term collaboration, and wish everyone a wonderful summer.

Stockholm July 16, 2026

Fredrik Dalborg
President and CEO

SECOND QUARTER

Net sales increased by 6 percent to SEK 2,721 million (2,578). Organic growth amounted to 3 percent and acquired growth to 3 percent. Organic growth was negatively impacted by the divestment of the endoscopy operations in the United Kingdom in December 2025, corresponding to SEK 30 million. Adjusted for the divestment, organic growth amounted to 4 percent. Exchange rate effects had a marginal impact on net sales during the quarter.

EBITA increased by 11 percent to SEK 342 million (307) and the EBITA margin amounted to 12.6 percent (11.9). Exchange rate effects had a marginal impact on EBITA.

Net financial items amounted to SEK -47 million (-54) and profit after financial items totalled SEK 189 million (146). Net financial items primarily include interest expenses related to the financing of previous acquisitions as well as exchange rate effects. Interest expenses amounted to SEK 43 million (52) and exchange rate losses to SEK 4 million (0).

Profit after tax increased by 30 percent to SEK 130 million (100), and the effective tax rate was 31 percent (29). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses.

Net sales quarter



EBITA quarter



Net sales



Adjusted EBITA



JANUARY – JUNE, 2026

Net sales increased by 2 percent to SEK 5,366 million (5,280). Growth, excluding exchange rate changes, amounted to 4 percent, of which organic growth was 2 percent and acquired growth was 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to SEK 93 million. Adjusted for the divestment, organic growth amounted to 3 percent. Exchange rate changes had a negative impact on net sales of SEK 113 million, corresponding to 2 percent.

EBITA increased by 4 percent to SEK 674 million (650) and the EBITA margin amounted to 12.6 percent (12.3). Currency effects had a negative impact on EBITA of SEK 13 million, corresponding to 2 percent.

Net financial items amounted to SEK -93 million (-117) and profit after financial items totalled SEK 372 million (318). Net financial items mainly include interest expenses related to the financing of previous acquisitions as well as exchange rate fluctuations. Interest expenses amounted to SEK 85 million (109) and exchange rate losses to SEK 6 million (1).

Profit after tax increased by 17 percent to SEK 258 million (220), and the effective tax rate was 31 percent (30). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses.





Financial position and cash flow

The equity ratio at the end of the interim period was 43 percent (43). Equity per share amounted to SEK 46.71 (44.67) and return on equity at the end of the interim period was 11 percent (11). Return on working capital (R/WC) was 61 percent (62).

The Group's net interest-bearing debt at the end of the interim period amounted to SEK 4,710 million (4,048), including pension liabilities of SEK 57 million (58), lease liabilities of SEK 542 million (504), contingent considerations corresponding to SEK 227 million (124) and provisions corresponding to SEK 27 million (29). Outstanding bank borrowings at the end of the interim period amounted to SEK 4,251 million (4,146), of which short-term bank borrowings totalled SEK 1,780 million (1,737).

Available liquidity, consisting of cash and bank balances, together with granted but unutilised credit facilities, amounted in total to SEK 1,381 million (1,447) at the end of interim period.

The net debt/equity ratio was 0.8, compared with 0.7 at the beginning of the year.

Cash flow from operating activities amounted to SEK 165 million (119) for the quarter. The increase was primarily attributable to a positive development in working capital. In total, the change in working capital during the quarter amounted to SEK -149 million (-180), mainly related to lower trade payables and an increase in inventory driven by the introduction of new products. During the interim period, payments for company acquisitions totalled SEK 303 million (138) and paid contingent considerations previous years' company acquisitions amounted to SEK 20 million (51).
Net investments in non-current assets amounted to SEK 132 million (122), primarily relating to investments in instruments for rental to customers. A dividend of SEK 182 million (91) was paid to the Parent Company's shareholders.

Long term financial goals

Profitability P/WC (%)



Profit growth adjusted EBITA (%)



Employees

At the end of the interim period, the number of employees was 2,360, compared to 2,295 at the beginning of the financial year. During the interim period, the completed acquisitions have led to an increase of 26 employees. The average number of employees for the last 12-month period was 2,320 (2,299).

Acquisitions

Acquisitions completed from the 2025 financial year are distributed among the Group's business areas as follows:

Company	Country	Time	Net Sales, SEKm*	Number of employees*	Business area
Edge Medical Ltd.	UK	April, 2025	90	20	Medtech
Pharmacold A/S	Denmark	December, 2025	38	20	Labtech
Opitek International ApS	Denmark	December, 2025	12	2	Medtech
BioSpectrum Ltd.	UK	March, 2026	75	16	Medtech
CoaChrom Diagnostica GmbH	Austria	April, 2026	110	10	Labtech
			325	**68**	

*Refers to conditions at the time of acquisition on a full-year basis.

In March all shares in BioSpectrum Ltd., United Kingdom, were acquired. BioSpectrum is a rapidly growing distributor of surgical solutions within urology, gynaecology and general surgery in the UK market. The company has annual sales of approximately GBP 6 million and 16 employees.

In April all shares in the Austrian company CoaChrom Diagnostica GmbH were acquired. CoaChrom is a distributor focusing on advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry. The company has annual sales of approximately EUR 10 million and 10 employees.

Net assets of acquired companies at the acquisition date

Fair value SEKm	Jun 30 2026
Intangible non-current assets	146
Other non-current assets	6
Inventories	26
Other current assets	39
Deferred tax liability/tax asset	-34
Other liabilities	-16
Acquired net assets	**167**
Goodwill	266
Consideration[1]	**433**
Less:	
Cash and cash equivalents in acquired businesses	-16
Contingent consideration not yet paid	-114
Effect on the Group's cash and cash equivalents	**303**

[1]The consideration is stated excluding acquisition expenses.

Acquired companies
The purchase price allocations are preliminary, as the net assets of the acquired companies have not yet been finally determined. For this year's acquisitions, the purchase consideration exceeded the carrying amount of the net assets of the acquired companies, resulting in goodwill and intangible assets.

Goodwill
The goodwill arising from the acquisition is attributable to the expectation that the Group's position in the relevant market will be strengthened, as well as the expertise developed in the acquired companies.

Contingent consideration
The contingent considerations included in the acquisitions are usually linked to the performance development of the respective companies.

During the interim period, contingent consideration of SEK 20 million relating to acquisitions in previous years was paid to BonsaiLab and Pharmacold.

Transaction costs
Transaction costs for acquisitions amount to a total of SEK 5 million and are recognized in selling expenses.

Revenue and earnings from acquired businesses
The acquisitions completed during the year have, from their respective acquisition dates, contributed a total of SEK 51 million to the Group's net sales and SEK 16 million to EBITA.

Had the acquired companies been consolidated from January 1, 2026, net sales and EBITA would have amounted to SEK 98 million and SEK 37 million, respectively.

Acquisitions after the end of the interim period
No acquisitions have been completed after the end of the interim period.

BUSINESS AREA

Labtech

The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.

SEKm	Q2 2026	Q2 2025	Δ %	Jan-Jun 2026	Jan-Jun 2025	Δ %	Jul 2025-Jun 2026	Full year 2025
Net sales	1,057	985	7	2,042	1,974	3	4,021	3,953
Organic growth, %	3	6		2	9			5
EBITA	142	122	16	271	242	12	524	495
EBITA margin, %	13.4	12.4		13.3	12.2		13.0	12.5

SECOND QUARTER

Net sales in Labtech increased by 7 percent to 1,057 million (985). Organic growth amounted to 3 percent and acquired growth to 4 percent. Exchange rate effects had a marginal positive impact on net sales during the quarter.

EBITA increased by 16 percent to SEK 142 million (122), corresponding to an EBITA margin of 13.4 percent (12.4). Exchange rate effects had a positive impact of SEK 1 million on EBITA, corresponding to 1 percent.

JANUARY – JUNE, 2026

Labtech's net sales increased by 3 percent to SEK 2,042 million (1,974). Adjusted for exchange rate changes, net sales increased by 5 percent, of which organic growth increased by 2 percent and acquired growth amounted to 3 percent. Exchange rate changes had a negative impact on net sales of SEK 29 million, corresponding to 1 percent.

EBITA increased by 12 percent to SEK 271 million (242), corresponding to an EBITA margin of 13.3 percent (12.2). Exchange rate changes had a negative impact on EBITA of SEK 3 million, corresponding to 1 percent.

Net sales quarter



Net sales January - June



Development in Labtech was strong during the quarter. Sales increased both organically and through acquisitions, while margins improved significantly. Previously won tenders continued to contribute positively, and several important new tenders were secured during the period.

The improvement efforts under way in several companies are yielding clear results in the form of higher margins and increased growth. This work is continuing with unchanged intensity.

Recently completed acquisitions made a clear contribution to the positive development in both sales and earnings.

The positive demand trend in the research segment identified in previous quarters continued and strengthened further.

Demand for diagnostic solutions that enable early and accurate test results, as well as more efficient processes, is increasing in both clinical operations and industry.

Investments in research and diagnostics are being made in several Eastern European countries, including Poland, Hungary, Romania and the Czech Republic, contributing to increased sales for several AddLife companies.

Net sales



Net sales per market 2026



Adjusted EBITA



Adjusted EBITA margin (%)



Medtech

In the Medtech business area, the subsidiaries offer products and services in the field of medical technology, as well as assistive equipment and digital solutions for home care. Medtech has two business units, Hospital and Homecare. The Medtech offering mainly focuses on publicly funded healthcare, home care and social care in Europe.

SEKm	Q2 2026	Q2 2025	Δ %	Jan-Jun 2026	Jan-Jun 2025	Δ %	Jul 2025-Jun 2026	Full year 2025
Net sales	1,666	1,594	5	3,327	3,308	1	6,514	6,495
Organic growth, %	3	2		1	1			2
EBITA	213	198	7	425	429	-1	960	964
EBITA margin, %	12.8	12.4		12.8	13.0		14.7	14.8

SECOND QUARTER

Net sales in Medtech increased by 5 percent to SEK 1,666 million (1,594). Organic growth amounted to 3 percent and acquired growth to 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to approximately SEK 30 million. Adjusted for the divestment, organic growth amounted to 5 percent. Exchange rate effects had a marginal negative impact on net sales during the quarter.

EBITA increased by 7 percent to SEK 213 million (198), corresponding to an EBITA margin of 12.8 percent (12.4). Exchange rate effects had a marginal negative impact on EBITA during the quarter.

JANUARY – JUNE, 2026

Medtech's net sales amounted to SEK 3,327 million (3,308). Adjusted for exchange rate changes, net sales increased by 3 percent, of which organic growth amounted to 1 percent and acquired growth to 2 percent. Adjusted for the divestment of the endoscopy business in the UK, organic growth amounted to 3 percent. Exchange rate changes had a negative impact on net sales of SEK 84 million, corresponding to 3 percent.

EBITA decreased by 1 percent to SEK 425 million (429), corresponding to an EBITA margin of 12.8 percent (13.0). Exchange rate changes had a negative impact on EBITA of SEK 11 million, corresponding to 3 percent.

Net sales quarter



Net sales January - June



Margins in Medtech strengthened during the quarter, to a large extent as a result of the ongoing work to increase the share of advanced products in the portfolio.

Growth and profitability were strong in the Nordic countries. In Spain, underlying growth was good, but sales development was negatively affected by week-long doctors' strikes in April, May and June. In the United Kingdom, sales development was weak, mainly due to a continued subdued market for capital goods. However, the order book for capital goods is strong.

Within Homecare, a number of improvement measures have been implemented in recent months. These measures have yielded good results, while simultaneously demand has increased. During the second quarter, Homecare reported strong growth and a clearly improved margin trend.

Improvement initiatives within ophthalmic surgery have been under way for an extended period and have included cost reductions, organisational changes, updates to the product portfolios and an increased sales focus. These initiatives have yielded results, and the companies within ophthalmic surgery have now demonstrated a clearly positive trend for some time.

Net sales



Net sales per market 2026



Adjusted EBITA



Adjusted EBITA margin (%)



For an independent life

AddLife's vision is to improve people's lives. Through products and solutions within Homecare, we aim to enable more people to live safely, independently and actively in their own homes.

The offering includes home adaptations, such as accessible bathrooms and kitchens, as well as solutions for both private homes and residential care facilities. It also includes assistive devices, ranging from portable and advanced aids to solutions that facilitate mobility, hygiene, communication and other everyday activities.

Welfare technology and digital solutions are an increasingly important part of the offering. These include personal safety alarms, fall sensors and other connected assistive devices that enhance safety for users while providing family members and healthcare professionals with better conditions for monitoring needs and providing the appropriate support. We also offer solutions for digital privacy-preserving supervision, fall detection and prevention, enabling safe, preventive and more resource-efficient healthcare and care services. Together, these solutions help bring healthcare and care services closer to the individual, improve quality of life and enable more efficient use of healthcare resources.

The Homecare business area consists of six well-established companies with combined sales of approximately SEK 700 million. The business has a strong position in the Nordic market and a growing export business, with sales in, among other markets, the United Kingdom, the Netherlands, Germany and Australia. AddLife's companies combine the distribution of products from international suppliers with proprietary products and have particular expertise in customised solutions, public procurement and long-term agreements. This provides control over product development, quality and the value chain, while enabling the companies to offer customised end-to-end solutions, including training, support, technical service and logistics.

The Homecare market is growing by approximately 10–12 percent annually and is driven by several strong, long-term societal trends. An ageing population, shortages of healthcare professionals and an increasing need for cost-effective care pathways are driving demand for solutions that enable healthcare and care services to be provided in the home. Digitalisation and welfare technology also create new opportunities to prevent risks, enhance safety and use healthcare resources more efficiently.

Key application areas within Homecare:

- **Home adaptations:** Bathrooms, kitchens and other areas at home are adapted to improve accessibility and enable people with disabilities to stay in their homes longer, with greater independence and safety.
- **Assistive devices:** Portable and advanced assistive devices facilitate everyday activities, mobility and personal care for older people and people with disabilities. The products are used both in private homes and in healthcare and care settings.
- **Welfare technology:** Digital solutions, such as personal safety alarms, fall sensors and connected products, can enhance safety at home, prevent risks and provide healthcare professionals and family members with better opportunities to monitor the individual's needs. AddLife offers welfare technology in several Nordic markets, including digital monitoring solutions for homes.
- **Accessible environments:** Adapted solutions for residential care facilities, institutions and private homes create safer and more functional environments for both users and staff. AddLife's offering includes assistive devices and digital solutions for publicly funded home healthcare and care services.

Export markets:

- United Kingdom
- Germany
- Netherlands
- Australia

10-12%
MARKET GROWTH

6
SUBSIDIARIES

~700
NET SALES, SEKm

Quarterly data

Net sales by business area

	2024			2025				2026	
SEKm	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**
Labtech	941	852	1,141	989	985	906	1,073	985	1,057
Medtech	1,615	1,494	1,679	1,714	1,594	1,524	1,663	1,661	1,666
Group items	-2	-2	-2	-1	-1	-1	-3	-1	-2
The Group	**2,554**	**2,344**	**2,818**	**2,702**	**2,578**	**2,429**	**2,733**	**2,645**	**2,721**

EBITA by business area

	2024			2025				2026	
SEKm	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**
Labtech	109	76	161	120	122	102	152	129	142
Medtech	200	153	195	231	198	177	357	212	213
Group items	-10	-6	-10	-8	-13	-9	-12	-9	-13
The Group	**299**	**223**	**346**	**343**	**307**	**270**	**497**	**332**	**342**

	2024			2025				2026	
%	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**
Labtech	11.6	8.9	14.1	12.1	12.4	11.2	14.1	13.1	13.4
Medtech	12.3	10.3	11.6	13.5	12.4	11.6	21.5	12.8	12.8
The Group	**11.7**	**9.5**	**12.3**	**12.7**	**11.9**	**11.1**	**18.2**	**12.5**	**12.6**

Adjusted EBITA / Adjusted EBITA margin by business area

	2024			2025				2026	
SEKm	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**
Labtech	109	76	161	120	122	102	152	129	142
Medtech	193	160	195	231	198	177	199	212	213
Group items	-10	-6	-10	-8	-13	-9	-12	-9	-13
The Group	**292**	**230**	**346**	**343**	**307**	**270**	**339**	**332**	**342**

	2024			2025				2026	
%	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**	**Q3**	**Q4**	**Q1**	**Q2**
Labtech	11.6	8.9	14.1	12.1	12.4	11.2	14.1	13.1	13.4
Medtech	11.9	10.7	11.6	13.5	12.4	11.6	12.0	12.8	12.8
The Group	**11.4**	**9.8**	**12.3**	**12.7**	**11.9**	**11.1**	**12.4**	**12.5**	**12.6**

Net sales and EBITA

Net sales by business area

SEKm	Q2 2026	Q2 2025	Δ %	Jan-Jun 2026	Jan-Jun 2025	Δ %	Jul 2025-Jun 2026	Full year 2025
Labtech	1,057	985	7	2,042	1,974	3	4,021	3,953
Medtech	1,666	1,594	5	3,327	3,308	1	6,514	6,495
Group items	-2	-1		-3	-2		-7	-6
The Group	**2,721**	**2,578**	**6**	**5,366**	**5,280**	**2**	**10,528**	**10,442**

EBITA / EBITA margin by business area and operating profit for the Group

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Labtech	142	122	271	242	524	495
Medtech	213	198	425	429	960	964
Group items	-13	-13	-22	-21	-43	-42
EBITA	**342**	**307**	**674**	**650**	**1,441**	**1,417**
Depreciation and write-down intangible assets	-106	-107	-209	-215	-418	-424
Operating profit	**236**	**200**	**465**	**435**	**1,023**	**993**
Finance income and expenses	-47	-54	-93	-117	-197	-221
Profit after financial items	**189**	**146**	**372**	**318**	**826**	**772**

%	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Labtech	13.4	12.4	13.3	12.2	13.0	12.5
Medtech	12.8	12.4	12.8	13.0	14.7	14.8
EBITA margin	**12.6**	**11.9**	**12.6**	**12.3**	**13.7**	**13.6**
Operating margin	**8.6**	**7.8**	**8.7**	**8.2**	**9.7**	**9.5**

Net sales by revenue type

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Products	731	704	1,467	1,435	2,827	2,795
Instruments	244	211	415	390	869	844
Services	82	70	160	149	325	314
Labtech	**1,057**	**985**	**2,042**	**1,974**	**4,021**	**3,953**
Products	1,375	1,343	2,773	2,716	5,419	5,362
Instruments	113	100	234	275	452	493
Services	178	151	320	317	643	640
Medtech	**1,666**	**1,594**	**3,327**	**3,308**	**6,514**	**6,495**
Group items	-2	-1	-3	-2	-7	-6
The Group	**2,721**	**2,578**	**5,366**	**5,280**	**10,528**	**10,442**

Sales per country

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Sweden	330	298	660	597	1,289	1,226
Ireland	321	322	657	668	1,319	1,330
UK	295	300	613	655	1,208	1,250
Spain	296	281	574	564	1,088	1,078
Norway	233	226	443	451	820	828
Italy	177	190	369	393	707	731
Denmark	173	158	348	332	697	681
Finland	157	136	291	268	579	556
Rest of Europe	665	567	1,246	1,177	2,605	2,536
Rest of the World	74	100	165	175	216	226
Total	**2,721**	**2,578**	**5,366**	**5,280**	**10,528**	**10,442**



Sales by region Q2 2026

Condensed consolidated income statement

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Net sales	2,721	2,578	5,366	5,280	10,528	10,442
Cost of sales	-1,647	-1,574	-3,269	-3,252	-6,482	-6,465
Gross profit	**1,074**	**1,004**	**2,097**	**2,028**	**4,046**	**3,977**
Selling expenses	-658	-644	-1,290	-1,278	-2,541	-2,529
Administrative expenses	-178	-155	-340	-302	-649	-611
Research and Development	-15	-14	-30	-29	-58	-57
Other operating income and expenses	13	9	28	16	225	213
Operating profit	**236**	**200**	**465**	**435**	**1,023**	**993**
Financial income and expenses	-47	-54	-93	-117	-197	-221
Profit after financial items	**189**	**146**	**372**	**318**	**826**	**772**
Tax	-59	-46	-114	-98	-226	-210
Profit for the period	**130**	**100**	**258**	**220**	**600**	**562**
Attributable to:						
Equity holders of the Parent Company	130	100	257	219	598	560
Non-controlling interests	0	0	1	1	2	2
Earnings per share before dilution, SEK	1.06	0.83	2.11	1.81	4.89	4.59
Earnings per share after dilution, SEK	1.06	0.83	2.11	1.81	4.89	4.59
Average number of shares after repurchases, '000s	121,864	121,864	121,864	121,864	121,864	121,864
Number of shares at end of the period, '000	121,864	121,864	121,864	121,864	121,864	121,864
EBITA	342	307	674	650	1,441	1,417
Depreciations and write-down included in operating expenses:						
Property, plant and equipment	-95	-94	-186	-186	-385	-385
Intangible non-current assets from acquisitions	-94	-97	-185	-195	-370	-380
Other intangible non-current assets	-12	-10	-24	-20	-48	-44

Consolidated statement of comprehensive income

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Profit for the period	**130**	**100**	**258**	**220**	**600**	**562**
Components that may be reclassified to profit for the period:						
Foreign currency translation differences for the period	83	139	171	-170	2	-339
Components that can not be reclassified to profit for the period:						
Revaluations of defined benefit pension plans	–	–	–	–	4	4
Tax attributable to items not to be reversed in profit or loss	–	–	–	–	-1	-1
Other comprehensive income	**83**	**139**	**171**	**-170**	**5**	**-336**
Total comprehensive income	**213**	**239**	**429**	**50**	**605**	**226**
Attributable to:						
Equity holders of the Parent Company	*213*	*239*	*428*	*50*	*601*	*223*
Non-controlling interests	*0*	*0*	*1*	*0*	4	*3*

Condensed consolidated balance sheet

SEKm	Jun 30 2026	Jun 30 2025	Dec 31 2025
Goodwill	5,853	5,559	5,449
Other intangible non-current assets	2,007	2,202	1,998
Property, plant and equipment	1,169	1,141	1,089
Financial non-current assets	27	31	26
Total non-current assets	**9,056**	**8,933**	**8,562**
Inventories	1,826	1,719	1,652
Current receivables	1,932	1,846	1,684
Cash and cash equivalents	394	253	813
Total current assets	**4,152**	**3,818**	**4,149**
Total assets	**13,208**	**12,751**	**12,711**
Total equity	5,697	5,268	5,447
Interest-bearing provisions	83	91	87
Non-interest-bearing provisions	344	349	324
Non-current interest-bearing liabilities	2,932	2,915	2,831
Non-current non-interest-bearing liabilities	33	32	31
Total non-current liabilities	**3,392**	**3,387**	**3,273**
Non-interest-bearing provisions	50	45	51
Current interest-bearing liabilities	2,089	2,119	1,943
Current non-interest-bearing liabilities	1,980	1,932	1,997
Total current liabilities	**4,119**	**4,096**	**3,991**
Total equity and liabilities	**13,208**	**12,751**	**12,711**

Condensed consolidated statement of changes in equity

	Jan 1 – Jun 30, 2026			Jan 1 – Dec 31, 2025		
SEKm	Equity excl. non-controlling interests	Non-controlling interests	Total equity	Equity excl. non-controlling interests	Non-controlling interests	Total equity
Amount at beginning of period	5,443	4	5,447	5,306	3	5,309
Share-based payments	3	–	3	5	–	5
Dividend	-182	–	-182	-91	-2	-93
Total comprehensive income	428	1	429	223	3	226
Amount at the end of the period	**5,692**	**5**	**5,697**	**5,443**	**4**	**5,447**

Condensed consolidated statement of cash flows

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Operating profit	236	200	465	435	1,023	993
Adjustment for items not included in cash flow	193	197	377	377	785	785
Interest paid	-43	-52	-85	-109	-178	-202
Interest received	4	1	5	1	8	4
Income tax paid	-76	-47	-116	-91	-242	-217
Changes in working capital	-149	-180	-377	-254	-94	29
Cash flow from operating activities	**165**	**119**	**269**	**359**	**1,302**	**1,392**
Net investments in non-current assets	-81	-58	-132	-122	-264	-254
Acquisitions and disposals	-239	-176	-323	-189	-381	-247
Change in other financial assets	0	0	-1	0	3	4
Cash flow from investing activities	**-320**	**-234**	**-456**	**-311**	**-642**	**-497**
Dividend paid to shareholders	-182	-91	-182	-91	-182	-91
Dividend paid to non-controlling interests	–	-2	–	-2	–	-2
Borrowings/repayment of borrowings, net	-3	111	0	107	-137	-30
Repayments on lease liability	-48	-46	-94	-92	-184	-182
Other financing activities	0	0	1	0	1	0
Cash flow from financing activities	**-233**	**-28**	**-275**	**-78**	**-502**	**-305**
Cash flow for the period	**-388**	**-143**	**-462**	**-30**	**158**	**590**
Cash and cash equivalents at beginning of period	771	368	813	331	253	331
Exchange differences on cash and cash equivalents	11	28	43	-48	-17	-108
Cash and cash equivalents at end of the period	**394**	**253**	**394**	**253**	**394**	**813**

Key figures

	Rolling 12 months ending				
	Jun 30 2026	Dec 31 2025	Jun 30 2025	Dec 31 2024	Dec 31 2023
Net sales, SEKm	10,528	10,442	10,442	10,286	9,685
EBITDA, SEKm	1,826	1,802	1,595	1,533	1,504
EBITA, SEKm	1,441	1,417	1,219	1,159	1,135
EBITA margin, %	13.7	13.6	11.7	11.3	11.7
Adjusted EBITA, SEKm	1,283	1,259	1,226	1,165	1,015
Adjusted EBITA margin, %	12.2	12.1	11.7	11.3	10.5
Profit growth EBITA, %	18	22	10	2	-7
Profit growth adjusted EBITA, %	5	8	14	14	-10
Return on working capital (P/WC), %	61	62	53	51	50
Profit for the period, SEKm	600	562	339	254	192
Return on equity, %	11	11	7	5	4
Financial net liabilities, SEKm	4,710	4,048	4,873	4,920	5,192
Financial net liabilities/EBITDA, multiple	2.6	2.2	3.1	3.2	3.5
Net debt/equity ratio, multiple	0.8	0.7	0.9	0.9	1.0
Equity ratio, %	43	43	41	41	39
Average number of employees	2,320	2,292	2,299	2,311	2,284
Number of employees at end of the period	2,360	2,295	2,322	2,256	2,301

Key ratios per share

Attributable to owners of the parent

	Jun 30 2026	Dec 31 2025	Jun 30 2025	Dec 31 2024	Dec 31 2023
Earnings per share (EPS), before dilution, SEK[1]	4.89	4.59	2.76	2.06	1.56
Earnings per share (EPS), after dilution, SEK[1]	4.89	4.59	2.76	2.06	1.56
Cash flow per share from operating activities, SEK[1]	10.69	11.42	9.52	8.98	6.35
Shareholders' equity per share, SEK	46.71	44.67	43.22	43.54	40.69
Average number of shares after repurchases, '000s[1]	121,864	121,864	121,864	121,863	121,856
Average number of shares adjusted for repurchases and dilution, '000s[1]	121,875	121,884	121,864	121,863	121,861
Number of shares outstanding at end of the period, '000s	121,864	121,864	121,864	121,864	121,857
Number of shares outstanding at end of the period after dilution, '000s	121,875	121,884	121,864	121,864	121,857

[1]Presented in rolling 12 months

Definitions can be found **here.**

Parent company

The Parent Company's net sales for the interim period amounted to SEK 37 million (36) and profit after financial items totalled SEK -90 million (117). The Parent Company's net financial debt at the end of the interim period amounted to SEK 4,217 million (3,740). Share capital at the end of the interim period amounted to SEK 62 million (62).

Parent Company condensed income statement

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025- Jun 2026	Full year 2025
Net sales	19	18	37	36	81	80
Administrative expenses	-34	-34	-63	-60	-120	-117
Operating profit	**-15**	**-16**	**-26**	**-24**	**-39**	**-37**
Interest income/expenses and similar items	-48	-61	-64	141	89	294
Profit after financial items	**-63**	**-77**	**-90**	**117**	**50**	**257**
Appropriations	–	–	–	–	-159	-159
Profit/loss before taxes	**-63**	**-77**	**-90**	**117**	**-109**	**98**
Tax	–	21	–	-15	15	0
Profit for the period	**-63**	**-56**	**-90**	**102**	**-94**	**98**

Parent Company condensed balance sheet

SEKm	Jun 30 2026	Jun 30 2025	Dec 31 2025
Intangible non-current assets	0	0	0
Property, plant and equipment	0	0	0
Financial non-current assets	7,856	8,041	8,246
Total non-current assets	**7,856**	**8,041**	**8,246**
Current receivables	308	419	504
Cash and cash equivalents	24	–	395
Total current assets	**332**	**419**	**899**
Total assets	**8,188**	**8,460**	**9,145**
Restricted equity	62	62	62
Unrestricted equity	2,391	2,663	2,661
Total equity	**2,453**	**2,725**	**2,723**
Non-current interest-bearing liabilities	2,511	2,520	2,449
Non-current non-interest-bearing liabilities	3	2	3
Total non-current liabilities	**2,514**	**2,522**	**2,452**
Current interest-bearing liabilities	3,190	3,170	3,570
Current non-interest-bearing liabilities	31	43	400
Total current liabilities	**3,221**	**3,213**	**3,970**
Total equity and liabilities	**8,188**	**8,460**	**9,145**

Accounting policies

The interim report has been prepared in accordance with IFRS Accounting Standards, applying IAS 34 Interim Financial Reporting. Disclosures according to IAS 34.16A are presented not only in the financial statements and accompanying notes but also in other parts of the interim report. The Parent Company's interim report has been prepared in accordance with the Swedish Annual Accounts Act and the Securities Market Act which is in compliance with recommendation RFR 2 Accounting for Legal Entities. The same accounting principles and calculation methods as in AddLife's 2025 annual report have been applied in this interim report.

Comparative figures in the interim period for income statement items refer to the value for the period January – June, 2025 and for balance sheet items as of December 31, 2025, unless otherwise stated.

New or amended accounting policies from 2026 onwards

IFRS 18 and related amendments to other standards shall be applied for financial years beginning on or after 1 January 2027, with retrospective application. The new standard, which has been adopted by the EU, replaces IAS 1. The standard does not affect the recognition or measurement of items in the financial statements, but only results in changes to presentation and disclosures. An analysis of the effects of the standard on the Group is in progress. The standard has not been early adopted.

No other new or amended accounting standards or interpretations approved for application from 2026 are assessed to have any material effect on the Group’s financial statements.

Information on Global Minimum Tax

The Group is covered by the OECD's model rules for Pillar II. The Group's exposure to the legislation under Pillar II has been calculated and analyzed. The Company’s assessment is that Pillar II has no material effect for the second quarter 2026.

Risks and uncertainties

The geopolitical situation in Ukraine and the Middle East has not had any material direct impact on AddLife’s financial reports during the first half of 2026. However, continued geopolitical and trade policy uncertainty may indirectly affect the availability of products and components, supply chains, freight and energy costs, as well as public healthcare and research budgets.

AddLife’s operations are primarily European, with approximately 95 percent of sales and 80 percent of purchases taking place in Europe, which limits direct exposure. At the same time, subcontractors and components further down the supply chain may be affected by tariffs, trade barriers, sanctions and international transport disruptions.

AddLife closely monitors developments relating to trade barriers, inflation, raw material, component, energy and freight costs, interest rates, as well as effects on customer demand and willingness to invest. For further information, reference is made to the section “Risks and uncertainties” in the administration report in AddLife’s 2025 Annual Report. The Parent Company is indirectly affected by the above risks and uncertainties through its function within the Group.

Transactions with related parties

No related party transactions have taken place during the interim period that have had a material impact on the Group’s financial position or results.

Financial instruments

Fair values on financial instruments

The fair value and carrying amount are recognized in the balance sheet as shown in the table below. For quoted securities, the fair value is determined on the basis of the asset's quoted price in an active market, level 1. At the reporting date the Group had no items in this category. For currency contracts and embedded derivatives, the fair value is determined on the basis of observable market data, level 2. For contingent considerations, a cash flow-based valuation is performed, which is not based on observable market data, level 3. For the Group's other financial assets and liabilities, fair value is estimated to essentially correspond to the carrying amount.

	Jun 30, 2026			Dec 31, 2025		
SEKm	Carrying amount	Level 2	Level 3	Carrying amount	Level 2	Level 3
Derivatives measured at fair value through profit or loss	0	0	–	0	0	–
Total financial assets at fair value per level	**0**	**0**	**–**	**0**	**0**	**–**
Derivatives measured at fair value through profit or loss	0	0	–	0	0	–
Contingent considerations	227	–	227	124	–	124
Total financial liabilities at fair value per level	**227**	**0**	**227**	**124**	**0**	**124**

Contingent considerations

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Amount at beginning of period	**107**	**90**	**124**	**106**	**107**	**106**
Acquisitions during the period	114	54	114	54	134	74
Consideration paid	–	-38	-20	-51	-20	-51
Revaluation through profit or loss	–	–	1	–	1	–
Interest expenses	1	1	2	1	4	3
Exchange differences	5	0	6	-3	1	-8
Amount at the end of the period	**227**	**107**	**227**	**107**	**227**	**124**

Pledged assets and contingent liabilities

SEKm	Jun 30 2026	Jun 30 2025	Dec 31 2025
Contingent liabilities	50	52	50

Significant events after the end of the interim period

No events of material significance for the Group have occurred after the end of the interim period.

Affirmation

The Board of Directors and the President deem that the interim report gives a true and fair picture of the Company's and the Group's operations, position and earnings, and describes the significant risks and uncertainty factors to which the Company and the Group are exposed.

Stockholm July 16, 2026

Johan Sjö
Chairman of the Board

Eva Nilsagård
Director

Eva Elmstedt
Director

Fredrik Rågmark
Director

Kristina Patek
Director

Stefan Hedelius
Director

Fredrik Dalborg
President and CEO

This interim report has not been subject to review by the company's auditors.

Definitions

Number of employees at the end of the period	The number of employees in the Group at the end of the reporting period, taking into account the degree of employment. *This measure is used to know how many employees the Group has at the end of the year.*
Return on equity	Profit/loss after tax attributable to shareholders, as a percentage of shareholders' proportion of average equity. *Return on equity measures from an ownership perspective the return that is given on the owners' invested capital.*
Return on working capital (P/WC)	EBITA in relation to average working capital. *P/WC is used to analyse profitability and encourage high EBITA earnings and low working capital requirements.*
EBITA	Operating profit before amortization and write-down of intangible assets. *EBITA is used to analyse profitability generated by operational activities.*
EBITA margin	EBITA as a percentage of net sales. *The EBITA margin is used to analyze value creation from the operating activities.*
EBITDA	Operating profit before depreciation, amortization and write-down. *EBITDA is used to analyse profitability generated by operational activities.*
Equity per share	Shareholders' proportion of equity divided by the number of shares outstanding at the end of the reporting period.
Financial net	Financial income minus financial expenses. *Used to describe the development of the Group's financial activities.*
Acquired growth	Changes in net sales attributable to business acquisitions compared to the same period the previous year. *Acquired growth is used as a component to describe the development of the Group's net sales, where acquired growth is distinguished from organic growth, divestments, and currency effects.*
Adjusted EBITA	EBITA excluding one-off costs. *Increases the comparability of EBITA over time as it is adjusted for the impact of items considered to be non-recurring in nature and therefore do not reflect the underlying operations.*
Adjusted EBITA margin	Adjusted EBITA in relation to net sales. *Used to measure the company's profitability excluding the impact of items considered to be non-recurring in nature and therefore do not reflect the underlying operations.*
One-off costs	Primarily refers to restructuring costs and revaluation of contingent considerations. Other non-recurring items may also be reported as one-off costs if this provides a more accurate view of the underlying operating result.

Cash flow from operating activities per share	Cash flow from operating activities, divided by the average number of shares. *The measure is used to allow investors to easily analyze the amount of surplus from ongoing operations generated per share.*
Net investments in fixed assets	Investments in fixed assets minus sales of fixed assets. *The measure is used to analyze the Group's investments in the renewal and development of tangible fixed assets.*
Net debt/equity ratio	Financial net liabilities in relation to shareholders' equity. *Net debt/equity ratio is used to analyse financial risk.*
Organic growth	Changes in net sales excluding currency effects and acquisitions/divestments compared to the same period the previous year. *Organic growth is used to analyze the underlying sales growth driven by changes in volume, product range, and price for similar products between different periods.*
Profit after financial items	Profit/loss for the period before tax. *Used to analyse the business' profitability including financial activities*
Earnings per share	Shareholders' share of the period's result divided by the number of shares outstanding at the end of the reporting period.
Earnings per share before dilution	Shareholders' share of the period's result divided by the average number of outstanding shares.
Earnings per share after dilution	Shareholders' share of the period's result divided by a weighted average of the number of outstanding shares, adjusted for the additional number of shares upon the exercise of outstanding options.
Profit growth EBITA	The period's EBITA decreased by previous period's EBITA divided by the previous period's EBITA. *Profit growth EBITA is used to analyse asset-creating generated from operational activities.*
Financial net liabilities	Interest-bearing liabilities and interest-bearing provisions, less cash and cash equivalents. *Net debt is used to monitor debt development and analyse financial leverage and any necessary refinancing.*
Financial net liabilities/EBITDA	Financial net liabilities divided by EBITDA. *Financial net liabilities compared with EBITDA provides a key financial indicator for financial net liabilities in relation to cash-generated operating profit; i.e., an indication of the ability of the business to pay its debts. This measure is generally used by financial institutions as a measure of creditworthiness.*
Working capital	Sum of inventories and accounts receivable, less accounts payable. In the calculation of P/WC, average working capital is used. *Working capital is used to analyse how much working capital is tied up in the business.*
Equity ratio	Equity including minority interest as a percentage of total assets. *The equity ratio is used to analyse financial risk and shows how much of the assets are financed with equity.*

Alternative performance measures

This report contains financial key figures in accordance with the frameworks applied by AddLife, which are based on IFRS. In addition, there are alternative performance measures (APM) that cannot be directly extracted or derived from the financial statements. These key figures are essential for understanding and evaluating AddLife's operations and financial position. They should not be seen as a replacement for the measures defined according to IFRS but rather as a complement to the financial reporting. Since not all companies calculate financial measures in the same way, these are not always comparable with measures used by other companies. The key figures are presented below and commented on in other parts of the interim period.

Return on equity

SEKm	Jun 30 2026	Jun 30 2025	Full year 2025
Profit/loss for the period attributable to shareholders (rolling 12 months)	598	337	560
Equity attributable to shareholders, average	5,476	5,198	5,288
Return on equity, %	**11**	**7**	**11**

Return on working capital (P/WC)

SEKm	Jun 30 2026	Jun 30 2025	Full year 2025
EBITA (rolling 12 months)	1,441	1,219	1,417
Inventories, average	1,735	1,748	1,713
Accounts receivable, average	1,614	1,556	1,586
Accounts payable, average	-1,004	-1,024	-1,013
Working capital, average	**2,345**	**2,280**	**2,286**
Return on working capital, %	**61**	**53**	**62**

EBITA and EBITDA

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
Operating profit	236	200	465	435	1,023	993
Amortization and impairment of intangible assets	106	107	209	215	418	424
EBITA	**342**	**307**	**674**	**650**	**1,441**	**1,417**
Depreciation and impairment of tangible assets	95	94	186	186	385	385
EBITDA	**437**	**401**	**860**	**836**	**1,826**	**1,802**

Adjusted EBITA

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
EBITA	342	307	674	650	1,441	1,417
One-off costs						
Sale of business	–	–	–	–	-158	-158
Adjusted EBITA	**342**	**307**	**674**	**650**	**1,283**	**1,259**

EBITA margin / Adjusted EBITA margin

SEKm	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Jul 2025-Jun 2026	Full year 2025
EBITA	342	307	674	650	1,441	1,417
Net sales	2,721	2,578	5,366	5,280	10,528	10,442
EBITA margin, %	**12.6**	**11.9**	**12.6**	**12.3**	**13.7**	**13.6**
Adjusted EBITA	342	307	674	650	1,283	1,259
Adjusted EBITA margin, %	**12.6**	**11.9**	**12.6**	**12.3**	**12.2**	**12.1**

Organic growth

	Labtech		Medtech		The Group[1]	
%	Q2 2026	Q2 2025	Q2 2026	Q2 2025	Q2 2026	Q2 2025
Total growth	7.3	4.8	4.6	-1.4	5.6	0.9
(-) Currency effect	0.5	-4.0	-0.2	-4.5	0.1	-4.2
(-) Acquired growth	3.9	2.7	1.8	1.5	2.6	1.9
Organic growth	**2.9**	**6.1**	**3.0**	**1.6**	**2.9**	**3.2**

	Labtech		Medtech		The Group[1]	
SEKm	Q2 2026	Q2 2025	Q2 2026	Q2 2025	Q2 2026	Q2 2025
Total growth	72	44	72	-21	143	24
(-) Currency effect	4	-38	-4	-70	1	-110
(-) Acquired growth	39	25	28	24	67	50
Organic growth	**29**	**57**	**48**	**25**	**75**	**84**

	Labtech		Medtech		The Group[1]	
%	Jan-Jun 2026	Jan-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Jun 2026	Jan-Jun 2025
Total growth	3.5	9.4	0.6	-0.5	1.6	3.0
(-) Currency effect	-1.4	-2.4	-2.5	-2.2	-2.2	-2.3
(-) Acquired growth	2.6	2.8	1.9	0.7	2.2	1.5
Organic growth	**2.3**	**9.0**	**1.2**	**1.0**	**1.6**	**3.8**

	Labtech		Medtech		The Group[1]	
SEKm	Jan-Jun 2026	Jan-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Jun 2026	Jan-Jun 2025
Total growth	68	170	19	-15	86	156
(-) Currency effect	-29	-44	-84	-72	-113	-116
(-) Acquired growth	52	52	62	24	114	76
Organic growth	**45**	**162**	**41**	**33**	**85**	**196**

[1]The Group includes eliminations

Profit growth EBITA / Profit growth adjusted EBITA

SEKm	Jun 30 2026	Jun 30 2025	Full year 2025
EBITA (rolling 12 months)	1,441	1,219	1,417
(-) Previous year's EBITA (rolling 12 months)	1,219	1,112	1,159
EBITA growth	**222**	**107**	**258**
Profit growth EBITA, %	**18**	**10**	**22**
Adjusted EBITA (rolling 12 months)	1,283	1,226	1,259
(-) Previous year's adjusted EBITA (rolling 12 months)	1,226	1,075	1,165
Adjusted EBITA growth	**57**	**151**	**94**
Profit growth adjusted EBITA, %	**5**	**14**	**8**

Financial net liabilities and Net debt/equity ratio

SEKm	Jun 30 2026	Jun 30 2025	Full year 2025
Borrowing	4,251	4,410	4,146
Cash and cash equivalents	-394	-253	-813
Financial net debt	**3,857**	**4,157**	**3,333**
Pension liability	57	62	58
Lease liability	542	518	504
Contingent considerations	227	107	124
Provisions	27	29	29
Net interest-bearing debt	**4,710**	**4,873**	**4,048**
Total equity	5,697	5,268	5,447
Net debt/equity ratio, multiple	**0.8**	**0.9**	**0.7**

Financial net liabilities/EBITDA

SEKm	Jun 30 2026	Jun 30 2025	Full year 2025
Net interest-bearing debt	4,710	4,873	4,048
EBITDA (rolling 12 months)	1,826	1,595	1,802
Financial net liabilities/EBITDA, multiple	**2.6**	**3.1**	**2.2**

Equity ratio

SEKm	Jun 30 2026	Jun 30 2025	Full year 2025
Total equity	5,697	5,268	5,447
Total assets	13,208	12,751	12,711
Equity ratio, %	**43**	**41**	**43**

The share

The share capital at the end of the interim period amounted to SEK 62 million (62).

The number of repurchased own shares amounts to 586,189 Class B, corresponding to 0.48 percent of the total number of shares and 0.36 percent of the votes. The average purchase price for shares held in treasury amounts to SEK 100.56 per share. The average number of treasury shares held during the interim period was 586,189 (586,189). The share price at June 30, 2026, was SEK 163.40.

AddLife has an outstanding incentive programme based on call options, corresponding to a total of 205,800 B shares. Issued call options on repurchased shares have resulted in a calculated dilution effect based on average share price for the interim period of approximately 0.0 percent (0.0). During the interim period, the 2022/2026 programme expired without impact, as the exercise price during the exercise period exceeded the share price.

AddLife has two outstanding incentive programmes based on performance shares corresponding to a maximum of 169,566 of the Company's Class B shares, which represents approximately 0.1 percent of the total number of shares. Participants receive performance shares provided that employment continues, the investment shares are retained, and the performance conditions are met. These are based on the average annual profit growth (EBITA) during the respective measurement period, as well as sustainability-related goals.

During the interim period, SEK 3 million (2) has been expensed as a result of the program.

On May 6, 2026, the Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to establish an additional long-term performance share-based incentive programme comprising no more than 150,500 Class B shares in the Company. The investment period runs until August 31, 2026.

On June 30, 2026, the number of shareholders amounted to 10,985, of which 64.93 percent are Swedish owners with respect to capital share. The 10 largest shareholders controlled 51.67 percent of number of capital and 62.45 percent of votes.

For further information about the share, see AddLife's website: **add.life/en/investors/the-share**

Incentive programmes based on call options

Outstanding programmes	Number of warrants	Corresponding number of shares	Percentage of total number of shares, %	Exercise price	Exercise period
2023/2027	205,800	205,800	0.2	155.99	Jun 1, 2026 – Feb 26, 2027

Incentive programme based on performance shares

Outstanding programmes	Number of investment shares	Corresponding maximum number of performance shares	Percentage of total number of shares, %	Vesting period	Measurement period
LTIP 2025	13,064	61,806	0.1	Aug 31, 2025 – Aug 31, 2028	Jan 1, 2025 – Dec 31, 2027
LTIP 2024	22,565	107,760	0.1	Aug 31, 2024 – Aug 31, 2027	Jan 1, 2024 – Dec 31, 2026
Total	**35,629**	**169,566**			

Shareholders

			Share in %	
Jun 30, 2026	**Class A-shares**	**Class B-shares**	**of capital**	**of votes**
RoosGruppen AB	2,256,408	3,838,841	4.98	16.14
Tom Hedelius	2,066,572	–	1.69	12.63
AMF Fonder	–	11,730,603	9.58	7.17
SEB Fonder	–	9,745,878	7.96	5.96
Cliens Fonder	–	6,987,932	5.71	4.27
Odin Fonder	–	6,830,008	5.58	4.17
Fjärde AP-fonden	–	5,527,391	4.51	3.38
Swedbank Robur Fonder	–	5,271,011	4.30	3.22
Vanguard Funds	–	4,669,212	3.81	2.85
Fidelity Mutual Funds	–	4,347,562	3.55	2.66
Total the 10 biggest shareholders	**4,322,980**	**58,948,438**	**51.67**	**62.45**
Other shareholders	249,816	58,342,827	47.85	37.19
Total outstanding shares	**4,572,796**	**117,291,265**	**99.52**	**99.64**
Repurchased own shares Class B	–	586,189	0.48	0.36
Total registered shares	**4,572,796**	**117,877,454**	**100.00**	**100.00**

Source: Euroclear

Video conference

Investors, analysts and the media are invited to a video conference where President and CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online.

The video conference will be held at 9:00 a.m. CEST on July 16, 2026.
If you wish to participate via video conference, **please follow this link>>**

The presentation is also available on **AddLife YouTube >>**

Financial calendar

- The interim report for January 1 – September 30, 2026, will be published on October 21, 2026
- Year-end report for January 1 – December 31, 2026, will be published on February 3, 2027
- The interim report for January 1 – March 31, 2027, will be published on April 29, 2027
- The Annual General Meeting (AGM) of AddLife AB (publ) will be held on May 4, 2027, at 4 p.m. CEST, Stockholm
- The interim report for January 1 – June 30, 2027, will be published on July 16, 2027

FOR FURTHER INFORMATION, PLEASE CONTACT:
Fredrik Dalborg, President and CEO, +46 70 516 09 01
Christina Rubenhag, CFO, +46 70 546 72 22

AddLife's interim report is published in Swedish and in an English translation. The Swedish version takes precedence in the event of any discrepancies between the two versions.

VISION

To improve people's lives by being a leading and value-creating partner in Life Science.

BUSINESS IDEA

AddLife adds value for its customers operating in the healthcare sector, from research to care. This is done by offering high-quality, cost-effective service and product solutions to both the private and public sectors in Europe.

CORE VALUES

Simplicity – Responsibility – Commitment – Innovation. The Group's core values guide AddLife's entrepreneurial business model.

ADDLIFE IN BRIEF
AddLife is an independent partner in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors in Europe. AddLife has 2,300 employees in about 85 operating subsidiaries. The Group currently has net sales of more than SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.



This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CEST on July 16, 2026.

AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. info@add.life, www.add.life, corporate identity number 556995-8126